The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Warning: Avoid Use of NSAIDs after Week 20 of Pregnancy

FDA Warning: Avoid Use of NSAIDs after Week 20 of Pregnancy

October 28, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On Oct. 15, the U.S. Food & Drug Administration (FDA) issued a warning that the use of non-steroidal anti-inflammatory drugs (NSAIDs) at or around week 20 of pregnancy may cause rare, but serious, renal problems in a developing fetus. The use of NSAIDs may result in oligohydramnios, a condition consisting of low amniotic fluid levels.1 Amniotic fluid provides a protective cushion and helps fetal development of the lungs, digestive system and muscles. Around week 20, the developing fetus’ kidneys  produce most of the amniotic fluid, so kidney problems can lead to low levels of amniotic fluid.

You Might Also Like
  • FDA Issues Stronger NSAIDs Warning
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • FDA Strengthens Warning Label for Certain Antiinflammatory Drugs
Explore This Issue
December 2020
Also By This Author
  • Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Although this safety concern is well known in some medical specialties, the FDA wanted to communicate this concern more widely and educate other healthcare professionals, as well as pregnant women and women who want to become pregnant. This warning concerns all NSAIDs, whether they are purchased over-the-counter or with a prescription.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA reviewed the medical literature, as well as cases submitted to the agency for data about oligohydramnios and fetal renal problems associated with NSAID use during pregnancy.

Through 2017, 35 cases were reported to the FDA about oligohydramnios and NSAIDs; all were serious. Of the FDA cases, two newborns who died had renal failure and confirmed oligohydramnios, with the mothers who took NSAIDs while pregnant. Three other newborns died with renal failure, but without confirmed oligohydramnios and with mothers who took NSAIDs while pregnant. The low amitotic fluid levels began as early as 20 weeks of pregnancy.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In 11 cases, oligohydramnios was detected during the pregnancies and amniotic fluid levels returned to normal after the NSAID was stopped. The information reported in these cases was similar to information reported in the medical literature. In the medical literature, oligohydramnios was noted during NSAID use for varying timeframes (e.g., 48 hours to many weeks). In most instances, low amniotic fluid levels reversed within 3–6 days after NSAID discontinuation. Resumption of NSAIDs led to a recurrence of low amniotic fluid levels.

The FDA is now recommending pregnant women avoid using NSAIDs at week 20 and beyond in pregnancy. (Note: The recommendations for NSAID prescribing have been that pregnant women should avoid taking NSAIDS at week 30, because NSAIDs may interfere with fetal lung maturation at that stage of pregnancy.)

If a healthcare professional deems it necessary to use an NSAID between weeks 20 and 30 of pregnancy, use should be limited to the lowest effective dose for the shortest duration. If NSAID use is longer than 48 hours, healthcare professionals should consider ultrasound monitoring of amniotic fluid, and the NSAID should be discontinued if oligohydramnios is found.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Safety Tagged With: FDA, kidney, oligohydramnios, pregnancy, Renal, safety warning, U.S. Food and Drug Administration (FDA), warningIssue: December 2020

You Might Also Like:
  • FDA Issues Stronger NSAIDs Warning
  • FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning
  • FDA Strengthens Warning Label for Certain Antiinflammatory Drugs
  • Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)